Living the Ferring Project
Family Commitment

At Ferring, we are working on research and development programmes toaddress some of the greatest challenges in reproductive medicine andmaternal health. We are also working to help improve access to care andtreatment, and to advocate for everyone’s right to build a family.
We are committed to:
1. Learning from patients to improve their treatment and care
2. Collaborating to reduce maternal and infant mortality
3. Closing gender and racial inequality gaps in reproductive medicine and maternal health
4. Working together to win hearts and minds
In this document you will find details on how Ferring is living up toeach of these areas of the Ferring Project Family Commitment.
To read the commitment in full click here.

Learning from patients to improvetheir treatment and care
How are we meeting this commitment?
• Ferring is committed to ensuring that the patient voice is heard consistently andcontinuously throughout the research, development and launch of our treatments. For
example, Ferring has established a global fertility council of patient group representatives
and fertility advocates, to ensure that fertility patient voices are heard and the patientcommunity can contribute to our research and development programmes and in areas
such as clinical trial and protocol design, product packaging, patient-focused materials
and patient support activities.
• At global and local level, Ferring organises patient advisory boards around different
conditions in reproductive medicine and maternal health.
• Ferring is committed to changing the lack of treatment options available forwomen who are pregnant or giving birth, driven by patient needs and preferences,and continues to invest and advance the field of reproductive medicine and maternal
health. As an example, in 2020 Ferring’s treatment for cervical ripening was approved
and launched in Japan, a milestone that was welcomed by patient advocacy groups.
This was the first cervical ripening treatment approved in Japan in over 20 years,
giving women in Japan greater choice of alternatives to mechanical methods ofcervical ripening.

Collaborating to reduce maternal
and infant mortality
How are we meeting this commitment?
• Ferring is working in collaboration with a number of leading organisations toreduce global maternal and infant mortality.
• As part of our commitment to reducing maternal mortality globally, Ferringcollaborated on the largest clinical trial in postpartum haemorrhage (PPH)
prevention involving nearly 30,000 women in 10 countries. The CHAMPION trial
was conducted by the World Health Organization (WHO), using Ferring’s heat-stablecarbetocin, and funded by MSD for Mothers. Ferring has also set out its commitment tomaking heat-stable carbetocin available at an affordable and sustainable access pricein public sector healthcare facilities in low and lower-middle income countries and is
supporting advocacy at local government level for heat-stable carbetocin.
• In addition to our own research programmes on preterm birth, Ferring established aresearch collaboration supporting March of Dimes and its network of prematurity research
centres, working to find the unknown causes of preterm birth and new ways to prevent
it. Thanks to Ferring funding, the March of Dimes was able to set up its first Prematurity
Research Center outside of the US, at Imperial College, London, UK.

• Ferring also supports GreenLamp, an organization dedicated to improving
conditions for mothers and babies in rural Ethiopia. Unreliable or non-existent power
supplies mean that women delivering at night may give birth in the dark, preventing
midwives being able to detect or manage complications. GreenLamp works to train
midwives and provide safer birthing conditions by supplying light and reliable power torural delivery rooms through their Solar Suitcase initiative, which Ferring has committed
to supporting for the next five years.
• Ferring is also a corporate partner for the Project Hope organization and has
previously supported the set-up of Project Hope’s midwife training in Philippines, aiming
to reduce maternal mortality rates.
• In China, Ferring is building partnerships with local non-governmentalorganisations (NGOs) to deliver disease education programmes in preterm birth.
For example, in partnership with the China Red Cross, Ferring China is supporting apatient assistance programme that aims to support women suffering from recurrent
miscarriage and preterm birth, with the goal of providing treatments to patients toprevent imminent preterm birth, in parallel to wider awareness raising on pregnancy
and prematurity. In addition, this initiative aims to continuously improve doctors’ skills inthe treatment of preterm delivery and foster interest in research on preterm birth and its
complications.
• Around the world, Ferring collaborates with regional and national obstetrics
societies to support research projects, research skills development and educational
programmes.

Closing gender and racial inequality
gaps in reproductive medicine and maternal
healthHow are we meeting this commitment?
• Ferring has long-term collaborations with patient groups and fertility advocatesaround the world to understand local community challenges in both awareness of andaccess to IVF treatment, and to co-create campaigns and programmes to address thesechallenges. For example, Ferring’s advocacy work with RESOLVE: The National Infertility
Association, has helped over 40 million people in the US gain insurance coverage forfertility treatment and preservation since 2015. In Colombia, the Ferring led awarenessand education programme PLAN M aims to empower women to better understand theirown fertility and options to build a family, from egg freezing to IVF.
• In Jamaica, Ferring has been supporting the advancement of surrogacy, workingwith partners to advise the Government of Jamaica to establish a policy and legislative
framework for the use of surrogacy in assisted reproductive health services.
• A gender data gap currently exists in healthcare, with investment in thedevelopment of treatments and services for women’s health significantly lower
than investment in men’s health. Over 60% of our research investment is focusedon the traditionally underserved and under-researched area of women’s reproductive
medicine and maternal health. Our current research programmes focus on conditions
with high unmet need including endometriosis, pregnancy-related conditions andinfertility. For example, one in 10 women of reproductive age worldwide suffer fromendometriosis, an extremely painful and often debilitating condition which can alsoaffect fertility. Ferring is currently running two phase 2 trials for a treatment targetedat helping women with endometriosis, from both a pain perspective and fertility
perspective. In total, Ferring has 13 ongoing clinical trials involving 5,000 patients in thereproductive medicine and maternal health field.
• In addition to Ferring-run research programmes, Ferring collaborates withlike-minded companies to drive forward research and patient care. For example,Ferring and Rebiotix, a Ferring company, have a research collaboration with
Karolinska Institutet focused on pregnancy loss and pre-term birth. The collaboration
is investigating the role of the microbiome in these areas of high unmet need through6 clinical studies involving approximately 6,000 women and babies. Ferring has alsoestablished a research collaboration with Igenomix to identify novel targets and diseasemechanisms in infertility and pregnancy-related conditions, with the goal of developing
innovative diagnostic and therapeutic strategies.
• In response to the COVID-19 pandemic, Ferring set up Investigational Research
Grants in Reproductive Medicine and Maternal Health (RMMH), designed toprovide funding to gather data related to conception, pregnancy and neonatal healthduring the COVID-19 pandemic, and ensure that people with fertility issues andpregnant women are not forgotten in research efforts. In total, Ferring awarded 71
grants to research projects from 22 different countries.

• As part of our commitment to dispelling the common myth that ‘infertility is a
women’s issue’ and to help ensure that, in future, women do not need to undergo IVF
when their male partner has a fertility issue, Ferring is researching factors contributing
to male fertility issues. We currently have two Ferring-owned research projects intomale fertility issues, as well as a collaboration with Chinese Academy of Sciences which
includes early basic research in reproductive biology including male infertility. Ferring isalso committed to working with male fertility advocates and is actively involving men in
the conversation around fertility through social media activities.
• To address racial inequalities in reproductive medicine and maternal health,Ferring has set up a racial equality taskforce to identify the ways in which Ferring
can address racial disparities in access to IVF treatment and maternal mortality in ourmajor markets. An innovation grants fund is also being set up, to support research
aimed at reducing these disparities.
• Excessive bleeding after birth, also known as postpartum haemorrhage(PPH), is the leading direct cause of maternal mortality worldwide, causing
approximately 70,000 deaths each year – 99% of which occur in low- and lower-middleincome countries. To address this inequality in maternal care, Ferring has also set
out its commitment to making heat-stable carbetocin available at an affordable andsustainable access price in public sector healthcare facilities in low and lower-middle
income countries and is supporting advocacy at local government level for heat-stablecarbetocin.

Working together to win hearts and minds
How are we meeting this commitment?
• As part of our Project Family Commitment, we are collaborating with people
impacted by medical fertility issues and those unable to build a family withoutmedical help, from across the globe. Our commitment covers the full patient journey,from conception to birth, and has been shaped around the urgent needs of our patientcommunities.
• Ferring conducted the global 1000 Dreams survey, a survey in 10 countries surveying
fertility patients and their partners, to better understand barriers in access to treatment.
The results of this study are being analysed from both a global and local perspective, tobetter understand how these barriers can be addressed and removed.
• In different countries around the world, Ferring is working to better understand andaddress barriers to IVF treatment, to empower people to understand their family building
options, and help them access the support they need throughout their journey.
• In the US, Ferring has set up the Fertility House Calls programme to virtuallyconnect potential parents with an experienced fertility specialist, from the comfortof their own home. By enabling patients to schedule an initial consult through theplatform, the programme is designed to empower people to take the first step in theirfertility journey.

• In Australia, Ferring created the MiFertility Plan App, a comprehensive tool to provide
practical and emotional support for patients through their fertility treatment cycle.
• Through online conversations, Ferring is helping to share stories of people going
through different family building journeys, amplifying their voices and helping toencourage empathy and understanding of fertility and family-building challenges.
• Through our #ProjectFamily conversation, we advocate for everyone’s right tobuild a family, and for people all over the world to be able to access the quality
care and treatments they need to build a family of their own. Examples of ourcampaigns include #FertilityAwks, an online series of family-building stories that uses
humour to raise awareness of the challenges people face on their fertility journey and tochange the conversation around fertility and family building, and #IVFandProud whichaims to reduce the stigma still associated with IVF by celebrating the people and families
here today thanks to IVF.
• Ferring has also supported the International Federation of Fertility Societies (IFFS)
on a campaign to help people around the world who are looking to safely start or resume
their fertility plans during the COVID-19 pandemic.

Building on our commitment
The Ferring Project Family Commitment inspires everything we do to build
families worldwide. We are always exploring new ways that we can support thecommunities we work with. Keep an eye out for more information and follow
us on Instagram, Facebook or Twitter for regular updates and contact us on
projectfamily@ferring.com to discuss how we can collaborate.